Successful treatment of methotrexate-associated classical Hodgkin lymphoma with brentuximab vedotin-combined chemotherapy: a case series

Methotrexate (MTX)-associated classical Hodgkin lymphoma (CHL) is unlikely to regress following discontinuation of MTX, and its treatment usually requires chemotherapy. Standard chemotherapy for CHL is the ABVD regimen, which contains pneumotoxic bleomycin. This can be problematic in MTX–CHL patient...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International journal of hematology 2020-05, Vol.111 (5), p.667-672
Hauptverfasser:	Ichikawa, Satoshi, Fukuhara, Noriko, Saito, Kei, Onodera, Koichi, Shirai, Tsuyoshi, Onishi, Yasushi, Yokoyama, Hisayuki, Fujii, Hiroshi, Ichinohasama, Ryo, Harigae, Hideo
Format:	Artikel
Sprache:	eng
Schlagworte:	Antineoplastic Combined Chemotherapy Protocols - therapeutic use Arthritis Autoimmune diseases Bleomycin Bleomycin - administration & dosage Brentuximab Vedotin - administration & dosage Chemotherapy Chronic conditions Complications Dermatomyositis Female Health services Hematology Hodgkin Disease - chemically induced Hodgkin Disease - drug therapy Hodgkin's lymphoma Humans Immunosuppressive agents Immunotherapy Lymphoma Medicine Medicine & Public Health Methotrexate Methotrexate - adverse effects Monoclonal antibodies Oncology Original Article Peripheral neuropathy Reduction Rheumatoid arthritis Systemic lupus erythematosus Targeted cancer therapy Toxicity Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!